New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest
Executive Summary
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
You may also be interested in...
Antibiotics Could See New Boosts From Medicare Rule, House Bill
US House looks to give BARDA more money for antibiotic development in next coronavirus relief bill, while Medicare broadens the types of antibiotics eligible for additional payments to include drugs approved under FDA's limited population antibiotic development pathway. But it's unclear whether the House funding can make it through the Senate and how meaningful the Medicare provision will be given few LPAD approvals.
Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise
Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011.
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.